Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V940 plus pembrolizumab as adjuvant treatment for resected non-small cell lung cancer
NL-OMON59956Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- May 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing V940 plus pembrolizumab with Placebo plus pembrolizumab (2 arms). Primary endpoint: Disease-free survival. Started May 2025; status: recruiting.
02
Drugs
intismeran autogenepembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59956.